BioCentury
ARTICLE | Politics & Policy

NHS England creates Sovaldi fund

April 18, 2014 12:53 AM UTC

NHS England approved L18.7 million ($31.3 million) in funding to treat advanced HCV patients with Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD). Treatment will be limited to patients at significant risk of death or who require liver transplantation, a population NHS estimates at about 500 patients. The U.K.'s NICE is reviewing Sovaldi for chronic HCV, with a first appraisal committee meeting scheduled for May 15. ...